Jun 25, 2019 1:00pm EDT Artelo Biosciences Announces Closing of $8.0 Million Public Offering and Partial Exercise and Closing of Over-Allotment Option
Jun 21, 2019 1:50pm EDT Artelo Biosciences Announces Pricing of $8.0 Million Public Offering and Uplisting to Nasdaq
May 08, 2019 4:05pm EDT Artelo Biosciences Retains Crescendo Communications, LLC for Investor Relations Services
Jan 03, 2019 8:00am EST Artelo Biosciences Retains Maxim Group LLC to Provide Financial Advisory and Investment Banking Services
Oct 09, 2018 8:00am EDT New Preclinical Cell-Line Data of Artelo Biosciences' ART27.13 Demonstrate Anti-Proliferative Activity in Tumor Models
Jul 03, 2018 8:00am EDT Artelo Biosciences Announces Five Year Commitment To Sponsor The Young Investigator Award At The International Cannabinoid Research Society Annual Symposium
Jun 12, 2018 8:00am EDT Artelo Biosciences Enters Into Global R&D Partnership With Syngene International And Aptus Clinical For The Clinical Development Of ART27.13 In Oncology
Apr 18, 2018 8:00am EDT Artelo Biosciences And Stony Brook University Announce Worldwide License Agreement For Portfolio Of Fatty Acid Binding Protein Inhibitor Drug Candidates
Jan 30, 2018 8:00am EST Artelo Biosciences And The NEOMED Institute Enter Into An Exclusive Global Option And License Agreement
